Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952010 · ClinicalTrials.gov registry record · Phase 1
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT06952010 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by Exelixis. The registered enrollment target is 75 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (66% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT06952010, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Conditions Studied
Interventions
- BIOLOGICAL XB628
Study Locations (10)
Texas
- Exelixis Clinical Site #9 - Houston
- Exelixis Clinical Site #2 - San Antonio
California
- Exelixis Site #5 - San Francisco
Connecticut
- Exelixis Site #4 - New Haven
Florida
- Exelixis Clinical Site #8 - Tampa
Massachusetts
- Exelixis Clinical Site #10 - Boston
Missouri
- Exelixis Site #6 - St Louis
New York
- Exelixis Site #7 - New York
North Carolina
- Exelixis Clinical Site #1 - Hickory
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06952010
The ClinicalTrials.gov registry entry for NCT06952010 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (66% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which XB628 is the first listed.
NCT06952010 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06952010 about?
NCT06952010 is a clinical study titled "A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors". This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
What is the current status of trial NCT06952010?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-05-01. Estimated completion is 2027-11.
What conditions does trial NCT06952010 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor.
What interventions are being tested in trial NCT06952010?
The interventions under investigation include: XB628 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06952010?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952010 being conducted?
This trial has 10 study locations across California, Connecticut, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.